Cargando…

Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report

Sotorasib is a KRAS(G12C) inhibitor that recently received approval for use in locally advanced or metastatic KRAS(G12C)-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeh, Justin, Marks, Jennifer A., Alzeer, Ali H., Sloan, Emily A., Varghese, Reshma, Paudel, Nitika, Reuss, Joshua E., Bergquist, Peter J., Liu, Stephen V., Kim, Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719091/ https://www.ncbi.nlm.nih.gov/pubmed/36471683 http://dx.doi.org/10.1016/j.jtocrr.2022.100428

Ejemplares similares

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
por: Ramalingam, Prasanna Srinivasan, et al.
Publicado: (2023)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
por: Iska, Sindu, et al.
Publicado: (2023)

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy
por: Kinahan, Holly
Publicado: (2022)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
por: Negrao, Marcelo V., et al.
Publicado: (2023)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
por: Bauml, Joshua M., et al.
Publicado: (2022)

Case Report: Case series: association between blood concentration and side effects of sotorasib
por: Shigaki, Ryota, et al.
Publicado: (2023)

Pleomorphic adenocarcinoma of the lacrimal gland with multiple intracranial and spinal metastases
por: Ahn, Jung Yong, et al.
Publicado: (2007)

Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma
por: Díez-Alonso, Manuel, et al.
Publicado: (2021)

A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition
por: Barrios-Bernal, Pedro, et al.
Publicado: (2023)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats
por: Du, Ping, et al.
Publicado: (2022)

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
por: Dy, Grace K., et al.
Publicado: (2023)

KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver
por: Popovic, M., et al.
Publicado: (2020)

Diffuse intracranial calcifications in a patient with untreated postoperative hypoparathyroidism
por: Bogler, Orly, et al.
Publicado: (2021)

Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?
por: Johnson, Mahlon D.
Publicado: (2016)

Sequential spinal and intracranial dural metastases in gastric adenocarcinoma: A case report
por: Kim, Hongsik, et al.
Publicado: (2018)

KRAS Mutation in Pediatric Intracranial Germ Cell Tumors
por: Khaiman, Chusana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ujfor5b4nck332f4t0pbq2atg4